Literature DB >> 21613929

Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration.

Louise Hecker1, Victor J Thannickal.   

Abstract

The pathogenesis idiopathic pulmonary of fibrosis and related fibrosis lung disorders are complex and poorly understood. This likely involves cellular mechanisms that result in loss of cellular homeostasis leading to aberrant alveolar wall remodeling through the excessive deposition of connective tissue matrices. Impaired tissue regeneration and dysregulation of cell death in lung fibroblasts and epithelial cells appear to be important in the initiation and progression of these disorders. This review summarizes current understanding in this area to stimulate research into the development of novel therapeutic strategies that prevent, halt or reverse the progression of lung fibrosis.

Entities:  

Mesh:

Year:  2011        PMID: 21613929     DOI: 10.1097/MAJ.0b013e31821a9d66

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

1.  Getting to the core of fibrosis: targeting redox imbalance in aging.

Authors:  Louise Hecker; Victor J Thannickal
Journal:  Ann Transl Med       Date:  2016-03

Review 2.  Mechanisms and consequences of oxidative stress in lung disease: therapeutic implications for an aging populace.

Authors:  Louise Hecker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

3.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

4.  Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging.

Authors:  Kosuke Kato; Naomi J Logsdon; Yoon-Joo Shin; Sunny Palumbo; Adam Knox; Joseph D Irish; Skye P Rounseville; Sydney R Rummel; Mohamed Mohamed; Kareem Ahmad; Johnny M Trinh; Deepali Kurundkar; Kenneth S Knox; Victor J Thannickal; Louise Hecker
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

5.  Biobanking and cryopreservation of human lung explants for omic analysis.

Authors:  Sarah G Chu; Sergio Poli De Frias; Yuichi Sakairi; Rachel S Kelly; Robert Chase; Kazuhisa Konishi; Ashley Blau; Ellen Tsai; Konstantin Tsoyi; Robert F Padera; Lynette M Sholl; Hilary J Goldberg; Hari R Mallidi; Phillip C Camp; Souheil Y El-Chemaly; Mark A Perrella; Augustine M K Choi; George R Washko; Benjamin A Raby; Ivan O Rosas
Journal:  Eur Respir J       Date:  2020-01-23       Impact factor: 33.795

Review 6.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Authors:  Lutz Wollin; Eva Wex; Alexander Pautsch; Gisela Schnapp; Katrin E Hostettler; Susanne Stowasser; Martin Kolb
Journal:  Eur Respir J       Date:  2015-03-05       Impact factor: 16.671

7.  Mouse Lung Fibroblast Resistance to Fas-Mediated Apoptosis Is Dependent on the Baculoviral Inhibitor of Apoptosis Protein 4 and the Cellular FLICE-Inhibitory Protein.

Authors:  Sanda A Predescu; Jian Zhang; Cristina Bardita; Monal Patel; Varun Godbole; Dan N Predescu
Journal:  Front Physiol       Date:  2017-03-14       Impact factor: 4.566

Review 8.  Mechanoregulation of the Myofibroblast in Wound Contraction, Scarring, and Fibrosis: Opportunities for New Therapeutic Intervention.

Authors:  Livingston Van De Water; Scott Varney; James J Tomasek
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-05       Impact factor: 4.730

Review 9.  Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis.

Authors:  David M Habiel; Cory Hogaboam
Journal:  Front Pharmacol       Date:  2014-01-23       Impact factor: 5.810

10.  Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

Authors:  K Griffiths; D M Habiel; J Jaffar; U Binder; W G Darby; C G Hosking; A Skerra; G P Westall; C M Hogaboam; M Foley
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.